Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30072173HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072174HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072175HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072176HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072177HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072178HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072179HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072180HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072181HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TVIS30072182HIVENSG00000097007.20protein_codingABL1YesNo25P00519
TCGA Plot Options
Drug Information
GeneABL1
DrugBank IDDB08901
Drug NamePonatinib
Target IDBE0000014
UniProt IDP00519
Regulation Typeinhibitor
PubMed IDs23409026
CitationsIqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T: Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era. PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8.
GroupsApproved; Investigational
Direct ClassificationBenzanilides
SMILESCN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1
PathwaysPonatinib Inhibition of BCR-ABL
PharmGKBPA165980594
ChEMBLCHEMBL1171837